AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01273818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin and cefazolin
Description: 80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation
Study NCT01273818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: 1000 mg cefazolin application intravenously 1 hour before operation
Study NCT02892942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide®
Description: 0.25 mg/day, starting on day 6 of Gonal-F®.
Study NCT02892942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide®
Description: 1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG
Study NCT01273818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin
Description: 80 mg gentamicin application intraoperatively
Study NCT04164589 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SCENAR 1NT-02.2
Description: The neuro-adaptative regulation will be carried out in vulvo-perineal and sacral area
Study NCT04164589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCENAR 1NT-02.2
Description: The neuro-adaptative regulation will be carried out in vulvo-perineal and sacral area
Study NCT01571271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Lithotripsy
Description: Laser Lithotripsy
Study NCT01571271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrohydraulic Lithotripsy
Description: Electrohydraulic Lithotripsy
Study NCT00730743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent Pringle maneuver
Description: Pringle maneuver is performed by isolation of the hepatoduodenal ligament which is then encircled and occluded with atraumatic vascular clamp. The clamp is applied for 15 minutes followed by unclamping for 5 minutes and repeated till end of liver transection. Limits of clamp cycle: 3 cycles for cirrhotic liver; 4 cycles for non-cirrhotic liver.
Study NCT01061489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auditory discrimination training
Description: 10-week neuroplasticity-based training (5 days/week, 1 hour each, PC-based), training at home
Study NCT01061489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical movement training
Description: 10-week training, small groups (2 days/week, 1 hour each) plus homework (3 days/week)
Study NCT00883753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg IV (maximum dose not exceeding 800 mg in a single infusion) every 4 weeks.
Study NCT03267355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound
Description: Indication of EUS
Study NCT04332419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Standard Imaging
Study NCT04332419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Additional Imaging
Study NCT04332419 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIRT with Y-90
Description: SIRT with Y-90 for palliative treatment of the liver malignancy.
Study NCT04457440 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Lifestyle Intervention
Description: This intervention is an abbreviated version of the Diabetes Prevention Program, which has been shown to be effective in reducing the risk of developing type 2 diabetes.
Study NCT04457440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention enhanced with Cognitive Behavioral Sleep Intervention
Description: This intervention will consist of the same 8 sessions of ILI with additions of sleep components in each session. The additional sleep components will include (a) psychoeducation about the importance of sleep in weight control and glycemic control, (b) sleep hygiene, (c) stimulus control, (d) modifying maladaptive beliefs about sleep, (e) and, setting individualized sleep schedule and reviewing sleep schedule.
Study NCT04934735 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program group
Description: The case-management rehabilitation program was conducted by a clinical social worker within the occupational medicine clinic and included several components:~1. Intake by a case manager~2. Referral to an occupational physician was within one week of the intake.~3. Charting an occupational rehabilitation program and timing the RTW date~4. Coordinating between the patients and their family, treating physicians, the employer, community services, and meeting with the patient's family - all on a needful basis.~5. Provision of a guidance booklet for employers on the RTW of cardiac patients.~6. The psychosocial intervention was tailored to the patient's emotional state, occupational needs, and specific requests.~7. Intensive follow-up sessions aimed to ensure that the rehabilitation program was carried out as planned.
Study NCT02493751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab (MSB0010718C)
Description: Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.
Study NCT02493751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
Study NCT00375245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin (sirolimus)
Description: Weekly oral doses, dose is assigned at the time of study entry
Study NCT00375245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapefruit Juice
Description: Daily oral doses starting during the second week on study.
Study NCT00432198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem (Myslee®)
Description: Oral
Study NCT00432198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral
Study NCT03195140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predictive Low Glucose Suspend
Description: Application of Predictive Low Glucose Suspend
Study NCT00677950 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal fusion
Description: Surgical procedure for lumbar spinal posterior decompression with concomitant posterolateral intertransverse process arthrodesis
Study NCT04638179 — intervention group
Intervention type: OTHER
Intervention: Not intervention.Use retrospective case contrl study.
Description: Use retrospective case contrl study.
Study NCT05374876 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hand Therapy Until CIPN
Description: Patient will participate until the time of onset of CIPN of the hands or through 84 days of treatment if no symptoms of CIPN.
Study NCT00719602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Taken orally twice daily
Study NCT00719602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: Taken orally twice daily
Study NCT02787876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegteograstim
Study NCT00677950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal fusion
Description: Surgical procedure for lumbar spinal posterior decompression with concomitant posterolateral intertransverse process arthrodesis
Study NCT02515669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO7239361
Description: Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
Study NCT02072577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: The student watched the video prepared individually in the ward where they were interned.~After this step, the student demonstrated again the procedure for oral hygiene.~At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
Study NCT03785301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Libre Flash Glucose Monitoring
Description: Freestyle Libre Flash Glucose Monitoring will be used in diabetic patients once a month for therr months to monitor glucose level. Patients could scan the sensor to get the glucose level at any time as they want. They could alter thier diet and exercise according to the glucose levels. Patients will be required to keep track of food and exercise during wearing FGM sensor. Physicians would adjust patients' medication according their glucose profile provided by FGM, A1c, and diet and exercise every month.
Study NCT00719602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: Taken orally twice daily
Study NCT00719602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Taken orally twice daily
Study NCT02515669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
Study NCT03731130 — intervention group
Intervention type: OTHER
Intervention: EORTC QLQ C30
Description: standardized questionaire
Study NCT01850810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Study Product
Study NCT01850810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Study Product
Study NCT02334709 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: A first line TKI will be administered according to the standard dosing of the drug for metastatic RCC during a 1-week run-in period after which SBRT will be delivered to the largest metastatic lesion concurrently with the TKI. The SBRT dose will be escalated in 3 dose levels, starting at 24Gy (8 Gy per fraction), followed by 30 Gy (10 Gy per fraction) and 36 Gy (12 Gy per fraction).
Study NCT00393822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifermin
Description: dose of 120 μg/kg, intravenous (IV) on day -3 for each cycle, for up to 6 chemotherapy cycles
Study NCT00393822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one bolus IV injection at 120 μg/kg/day of matched placebo
Study NCT02158494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance and Gait Training using neurostimulation modulation.
Description: CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
Study NCT02158494 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: The sham device is visually identical to the CN-NINM device, and offers a non-zero, minimally perceivable stimulation.
Study NCT01673685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable Oxygen
Study NCT03974217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib is a drug that stops the activity of a protein called poly (adenosine diphosphate \[ADP\]-ribose) polymerase or PARP. PARP is involved in repairing damage to the DNA within the cells. When PARP is turned off by Talazoparib in cancer cells, DNA damage cannot be repaired and leads to the death of the cancer cells.
Study NCT03974217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is a drug that is meant to inhibit DNA methylation to restore normal functions to genes and helps to support normal cell production in the bone marrow and the death of abnormal bone marrow cells.
Study NCT03737981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Given PO
Study NCT03737981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT03737981 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Given IV
Study NCT03737981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT03737981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Undergo observation
Study NCT03737981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT01265537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx:~0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4
Study NCT01265537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx~0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.
Study NCT01673685 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Portable Oxygen
Study NCT02594358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: 20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING
Study NCT03835715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Flexible doses (10-20 mg) of vortioxetine; 10 mg during the first week which may be increased up to 20 mg week 2-8
Study NCT00920543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Twice daily dosing
Study NCT00958451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: 1. Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;~2. Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks.
Study NCT00958451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: 1. If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.~2. If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.~3. If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks.
Study NCT04435197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Pre-operative Pembrolizumab+chemoradiotherapy
Study NCT03731130 — intervention group
Intervention type: OTHER
Intervention: EORTC QLQ CR29
Description: standardized questionaire
Study NCT04576234 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: entral feeding
Description: Intermittent enteral feeding group recieved intermittent feeding as the feed was given over a 24 hour period with intervals of rest (e.g. three hours feeding two hours rest)
Study NCT03354286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developmental & Technological Demands
Description: Education and training related to use of CGM in this age group
Study NCT03354286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Reduction
Description: Education and training on reducing distress
Study NCT03354286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition, Set Point, & C:I Ratio
Description: Education and training on how to use the HCL system to dose for different kinds of foods to improve glycemic control
Study NCT03354286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypoglycemia management
Description: Education and training on reducing worries of hypoglycemia
Study NCT03354286 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minimal Intervention
Description: Minimal intervention to simulate standard care - serves as the control group
Study NCT00002939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00002939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01845272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 32mg, amlodipine 10mg
Description: Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
Study NCT00920543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 100mcg
Description: Twice daily dosing
Study NCT00920543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 500mcg
Description: Twice daily dosing
Study NCT00920543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 250mcg
Description: Twice daily dosing
Study NCT00920543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSC 100/50mcg
Description: Twice daily dosing
Study NCT00920543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSC 250/50mcg
Description: Twice daily dosing
Study NCT00920543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSC 500/50mcg
Description: Twice daily dosing
Study NCT00003789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isolated limb perfusion
Description: Undergo isolated limb perfusion
Study NCT00003789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given via limb perfusion
Study NCT00003789 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant tumor necrosis factor family protein
Description: Given via slow injection into the arterial line
Study NCT00003789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00003789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03420677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of tones
Description: During NREM sleep, tones (max. 60 dB) will be played using a portable, safe, in-home device. This device records biosignals (e.g. brain activity) and precisely times the tones during NREM sleep. It was developed and produced by the ETH Zurich and approved for use in this study by Swissmedic
Study NCT03420677 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No application of tones
Description: This is the sham-control intervention; The device will only record biosignals but will not play tones.
Study NCT03901963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab 1800 mg will be administered by SC injection weekly during Cycles 1 and 2, every 2 weeks during Cycles 3 through 6, and every 4 weeks from Cycle 7 onward until confirmed progressive disease (PD), unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles.
Study NCT03901963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10 mg will be administered orally from Day 1 to Day 28 (continuously) of each 28-day cycle until confirmed PD, unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
Study NCT03901963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide 10 mg will be administered orally from Day 1 to Day 28 (continuously) of each 28-day cycle until confirmed PD, unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
Study NCT03555851 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.
Study NCT03555851 — intervention group
Intervention type: OTHER
Intervention: Specimen collection
Description: Buccal swabs will be obtained from donors for pharmacogenomics.
Study NCT02306161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02306161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT02306161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02306161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02306161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV
Study NCT02306161 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT02306161 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: Given IV
Study NCT02306161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV